drug combination
187 articles
Pancreatic Cancer: 2018 Highlights And Looking Forward to 2019
Dr. Allyson Ocean leads an overview of the new treatments and protocol from 2018 as well as what are the next steps in treatment for 2019.
The American Association for Cancer Research (AACR) Virtual Special Conference: Pancreatic Cancer Day One
Let’s Win and the Lustgarten Foundation present highlights of Day One of the AACR Virtual Special Conference on Pancreatic Cancer.
Platform Trial Increases Efficiency in Studying Immunotherapy
Dr. Elizabeth Jaffee is betting that three types of immunotherapy will rev up the immune system and make chemotherapy more effective in a platform trial.
A Look at MEK and Autophagy Inhibition
Dr. Conan Kinsey looks at the MEK pathway as way to make immunotherapy more effective for pancreatic cancer patients.
Cherishing the Simple Things
Elizabeth O’Connor has a PALB2 genetic mutation so her stage IV pancreatic cancer has responded to immunotherapy.
Slowing the Growth of Pancreatic Tumors Before Surgery
A chemoradiation clinical trial tests standard chemotherapy plus an anti-malaria drug and compares two types of radiation treatments, to slow tumor growth.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
AACR Special Conference Highlights Advances in Pancreatic Cancer Research
Here are some of the most interesting highlights from the 2024 AACR Special Conference on Pancreatic Cancer Research.
Researching More Second-Line Options for Pancreatic Cancer
Dr. Allyson Ocean explains the concept behind a novel second-line treatment being tested for metastatic pancreatic cancer.
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
Testing a New Approach to Treating Advanced Pancreatic Cancer
Scientists are testing a new drug that is an antagonist of stress hormone receptors, in combination with nab-paclitaxel, for advanced pancreatic cancer.
Testing Treatment Combinations to Make Surgery More Effective
Can losartan (a high blood pressure drug) and immunotherapy combined with standard chemotherapy and radiation be an effective combination against pancreatic cancer?
Slowing the Spread of Advanced Pancreatic Cancer
Researchers are testing a kinase inhibitor that is used to treat lung diseases, including a type of lung cancer, against pancreatic cancer.
Immunotherapy to Enhance Standard Chemotherapy for Advanced Pancreatic Cancer
Researchers are testing an immunotherapy drug approved for other advanced cancers for effectiveness against pancreatic cancer.
Helping Some Types of Chemotherapy Penetrate Pancreatic Tumors
A clinical trial looks at the effectiveness of PEGPH20 in helping chemotherapy penetrate the stroma of pancreatic tumors, to make them removable.